Drug: Tagitanlimab Drug: Capecitabine

Phase 1Small molecule

SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Drug: Tagitanlimab Drug: Capecitabine is one of 38 small molecule programs targeting Patients With Advanced Solid Tumors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Patients With Advanced Solid TumorsRecruiting

Patients With Advanced Solid TumorsPhase 1

Recruiting

Competition

Competitive Landscape

225 competitors in Patients With Advanced Solid Tumors

#DrugCompanyPhaseTrials

Halaven

Eisai

Phase 2

2 2

Ensacove

XXcovery Holdings, Inc.

Phase 2

1 3

Albumin-Bound Paclitaxel

Bristol-Myers Squibb

Phase 2

2 4

Carboplatin AUC-5

Merck & Co.

Phase 2

1 5

HRS-4642

JJiangsu HengRui Medicine Co., Ltd.

Phase 2

2 6

AK112

SSummit Therapeutics

Phase 2

1 7

Almonertinib

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 2

1 8

QL1706

Qilu Pharmaceutical Co., Ltd.

Phase 2

1 9

QL2107

Qilu Pharmaceutical Co., Ltd.

Phase 2

1 10

RMC-6236

Revolution Medicines

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Recruiting

Patients With Advanced Solid Tumors

NCT05367635

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

A Study of SKB315 in Patients With Advanced Solid Tumors

Recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 1·NCT05367635·246 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Drug: Tagitanlimab Drug: Capecitabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Drug: Tagitanlimab Drug: Capecitabine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Drug: Tagitanlimab Drug: Capecitabine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Drug: Tagitanlimab Drug: Capecitabine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News